The Patent Finder

Terms ending in 2026

Amgen Inc.

Every in-force patent on Amgen Inc.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 7,425,631Compounds and Methods of Use
In force
 · High confidence
Array Biopharma Inc.In forceHigh confidence
US 8,002,745Retractable Syringe with Plunger Disabling System
In force
 · High confidence
Amgen Inc.In forceHigh confidence
US 8,680,248Host Cells Comprising Alpha 1, 2 Mannosidase and Culture Methods Thereof
In force
 · Medium confidence
Amgen Inc.In forceMedium confidence
US 9,273,110Production of Glycoproteins Using Manganese
In force
 · Medium confidence
Amgen Inc.In forceMedium confidence
US 12,351,613Production of Glycoproteins Using Manganese
In force
 · Medium confidence
Amgen Inc.In forceMedium confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Amgen Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited